The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BELLUS Health Inc. (NASDAQ: BLU) who purchased shares between September 5, 2019 and July 5, 2020. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the BELLUS Health lawsuit alleges that while BLU-5937’s “high selectivity” contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company’s Phase 2 trial.
Shareholders have until May 17, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >